A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy

Inclusion Criteria: * Age 18 to 60, inclusive * In need of medial meniscectomy * Normal axial alignment * Stable knee- previous ligament reconstruction, if stable * Removal of at least 50% of the affected portion of the medial meniscus * Intact articular cartilage in posterior meniscal weight-bearing zone * Willingness to follow normal post-operative rehabilitation * Willingness to participate in follow-up for two years from the time of meniscectomy surgery * Ability to understand and willingness to sign consent form Exclusion Criteria: * Pregnant or lactating * ACL or other support structure damage confirmed at surgery * Grade III or IV cartilage damage (Cartilage loss greater than 50% thickness in area \>15mm on weight-bearing aspect of femoral condyle or tibial plateau) * Synvisc, steroid, or corticosteroid injections in preceding 3 months * Diffuse synovitis at time of arthroscopy * Inflammatory arthritis * Oral steroid, methotrexate therapy * Unable to follow post-operative exercise regimen or return for evaluations * Active alcohol or substance abuse within 6 months of study entry * Current and active tobacco product use * Patient is positive for HIV * Patient is positive for hepatitis (past history of Hepatitis A is allowed) * Any medical condition, which in the opinion of the clinical investigator, would interfere with the treatment or outcome of the patient * Indwelling pacemaker * Cerebral aneurysm clips * Ear, eye and penile implants with avian components * Electrical indwelling device such as bone stimulator * Indwelling magnets as tissue expander for future implants * Known allergy to avian, bovine or porcine protein